POOI

| www.hiv-druginteractions.org | | UNIVERS LIVERF |
|------------------------------|--------------------|-------------------|
| | Interaction Report | |

Report ID: Date Produced: 12 July 2025

| Antiretroviral Treatment | Co-medications |
|---|---------------------|
| Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) | Calcium supplements |

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org .

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) + Calcium supplements

As with other HIV integrase inhibitors, bictegravir may be subject to chelation by high concentrations of divalent cations which may result in reduced bictegravir concentrations. Bictegravir and calcium supplements can be coadministered simultaneously. The European product label for Biktarvy recommends they can be taken together without regard to food, but the US product label recommends to administer simultaneously with food. (The decision to administer with or without food should be decided on a case-by-case basis.) The simultaneous administration of calcium carbonate (1200 mg) and bictegravir with food did not significantly modify bictegravir exposure whereas exposure was decreased by 33% when coadministered in fasted conditions. No interaction is expected with emtricitabine and tenofovir alafenamide.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

The report is provided for information only. It is not intended to replace a consultation with an appropriately qualified health probation. Information presented relates only to known or supported effects of interacting medications, and is based on relevant to the relation of the probation of t